Next |
home / stock / algs / algs message board
Subject | By | Source | When |
---|---|---|---|
$ALGS 4Q22 results12/31/22 cash=$126M4Q22 cash burn=$16M: | DewDiligence | investorshub | 03/09/2023 9:45:09 PM |
$ALGS de-prioritizes HBV programreduces workforce 10%: | DewDiligence | investorshub | 02/08/2023 11:09:44 PM |
znewcar1: $ALGS 23% v4,7M c2.02 f42,815M H2.41 ML.84 gapNgo to HOD | znewcar1 | investorshangout | 01/17/2023 10:14:56 PM |
Might hit $3 today. | Laster | investorshub | 01/17/2023 3:08:08 PM |
Beautiful. Will pass $2 today. | Laster | investorshub | 01/17/2023 12:41:36 PM |
znewcar1: $ALGS 21% v948K c1.58 f42,8M H1.6 ML.84 | znewcar1 | investorshangout | 01/10/2023 10:29:12 PM |
Its running. | Laster | investorshub | 01/06/2023 2:15:20 PM |
$ALGS provides 2023 roadmap: | DewDiligence | investorshub | 01/05/2023 3:21:50 PM |
ALGS 3Q22 results9/30/22 cash=$142M3Q22 cash burn=$17M: | DewDiligence | investorshub | 11/02/2022 11:42:46 PM |
ALGS 2Q22 results6/30/22 cash=$159.3M(down from $183M @3/31/22): | DewDiligence | investorshub | 08/04/2022 8:25:04 PM |
$ALGSCash @3/31/22=$183M$23B burn in 1Q22: | DewDiligence | investorshub | 05/04/2022 9:49:40 PM |
$ALGS selects lead SARS-CoV-2 PIphase-1 expected to start | DewDiligence | investorshub | 04/04/2022 3:29:52 PM |
$ALGS discontinues another HBV candidate: | DewDiligence | investorshub | 03/22/2022 1:43:35 PM |
$ALGS 4Q21 financials12/31/21 cash=$205.8M: | DewDiligence | investorshub | 03/10/2022 9:57:06 PM |
Disclosure: I'm long $ENTA. | DewDiligence | investorshub | 02/17/2022 5:47:34 PM |
Two takeaways from today's Leerink webcast on $ALGS-9711 | DewDiligence | investorshub | 02/17/2022 5:47:11 PM |
Preclinical data on $ALGS-097111 protease inhibitor from 2021 CROI: | DewDiligence | investorshub | 02/17/2022 5:44:06 PM |
Link to Leerink webcast: | DewDiligence | investorshub | 02/17/2022 5:08:57 PM |
$ALGS--Bungee Jumping | oxnous | investorshub | 01/06/2022 9:37:28 PM |
ALGS -40%/PM on discontinuation of lead HBV candidate for lack of efficacy: | DewDiligence | investorshub | 01/06/2022 2:13:59 PM |
News, Short Squeeze, Breakout and More Instantly...
Aligos Therapeutics Inc. Company Name:
ALGS Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive...
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstr...
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused ...